Carbamazepine and Ototoxicity - a phase IV clinical study of FDA data

Summary:

Ototoxicity is reported only by a few people who take Carbamazepine.

The phase IV clinical study analyzes which people take Carbamazepine and have Ototoxicity. It is created by eHealthMe based on reports of 38,703 people who have side effects while taking Carbamazepine from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 20, 2022

38,703 people reported to have side effects when taking Carbamazepine.
Among them, 5 people (0.01%) have Ototoxicity.


What is Carbamazepine?

Carbamazepine has active ingredients of carbamazepine. It is often used in epilepsy. eHealthMe is studying from 39,553 Carbamazepine users for its effectiveness, alternative drugs and more.

What is Ototoxicity?

Ototoxicity (damage to the ear) is found to be associated with 599 drugs and 337 conditions by eHealthMe.

Number of Carbamazepine and Ototoxicity reports submitted per year:

Could Carbamazepine cause Ototoxicity?

Gender of people who have Ototoxicity when taking Carbamazepine *:

  • female: 80 %
  • male: 20 %

Age of people who have Ototoxicity when taking Carbamazepine *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 66.67 %
  • 50-59: 0.0 %
  • 60+: 33.33 %

Common drugs people take besides Carbamazepine *:

  1. Neurontin: 2 people, 40.00%
  2. Ethambutol Hydrochloride: 2 people, 40.00%
  3. Amikin: 2 people, 40.00%
  4. Warfarin Sodium: 1 person, 20.00%

Common side effects people have besides Ototoxicity *:

  1. Deafness Neurosensory: 2 people, 40.00%
  2. Petit Mal Epilepsy (absence seizure): 1 person, 20.00%
  3. Liver Function Tests Nos Abnormal: 1 person, 20.00%
  4. Extrapyramidal Disorder (involuntary muscle spasms in the face and neck): 1 person, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Carbamazepine and have Ototoxicity?

Check whether Ototoxicity is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

How severe was Ototoxicity and when was it recovered:

Expand to all the drugs that have ingredients of carbamazepine:

Alternative drugs to, pros and cons of Carbamazepine:

Common Carbamazepine side effects:

Browse all side effects of Carbamazepine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Ototoxicity treatments and more:

COVID vaccines that are related to Ototoxicity:

Common drugs associated with Ototoxicity:

All the drugs that are associated with Ototoxicity:

All the conditions that are associated with Ototoxicity:

How the study uses the data?

The study uses data from the FDA. It is based on carbamazepine (the active ingredients of Carbamazepine) and Carbamazepine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: